Rchr
J-GLOBAL ID:200901007296945890   Update date: Aug. 16, 2023

Shirakawa Toshiro

シラカワ トシロウ | Shirakawa Toshiro
Affiliation and department:
Job title: Professor
Research field  (1): Tumor diagnostics and therapeutics
Research keywords  (7): Cancer Immunology ,  prostate ,  vaccine ,  AMR ,  urogenital cancer ,  oral vaccine ,  gene therapy
Research theme for competitive and other funds  (31):
  • 2021 - 2024 腸管細胞の獲得免疫における動態評価
  • 2019 - 2022 尿路感染症における網羅的薬剤耐性機構の研究
  • 2019 - 2022 Development of a mucosal long peptide cancer vaccine using a membrane transport polymer as a carrier.
  • 2020 - 2022 Development of a novel oral vaccine against COVID-19
  • 2019 - 2022 【AMED】腸管免疫を利用した新規経口がんワクチンの開発
Show all
Papers (252):
  • Hideto Ueki, Koichi Kitagawa, Mako Kato, Shihoko Yanase, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, et al. An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model. Scientific reports. 2023. 13. 1. 9994-9994
  • Hikaru Minagawa, Yoshiko Hashii, Hiroko Nakajima, Fumihiro Fujiki, Soyoko Morimoto, Jun Nakata, Toshiro Shirakawa, Takane Katayama, Akihiro Tsuboi, Keiichi Ozono. Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. BMC cancer. 2023. 23. 1. 167-167
  • Ruhan A, Naoto Kunimura, Shoko Tominaga, Erika Hirata, Shunya Nishioka, Misato Uesugi, Rion Yamazaki, Hideto Ueki, Koichi Kitagawa, Masato Fujisawa, et al. A recombinant adenovirus vector containing the synNotch receptor gene for the treatment of triple-negative breast cancer. Frontiers in oncology. 2023. 13. 1147668-1147668
  • Jieying Yang, Li Fu, Toshiro Shirakawa, Tong Xiang. Editorial: Targeting tumor vasculature to enhance cancer immunotherapy. Frontiers in oncology. 2023. 13. 1199811-1199811
  • Natsuki Nakagawa, Yoshiko Hashii, Hisako Kayama, Ryu Okumura, Hiroko Nakajima, Hikaru Minagawa, Soyoko Morimoto, Fumihiro Fujiki, Jun Nakata, Toshiro Shirakawa, et al. An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia. Cancer immunology, immunotherapy : CII. 2022
more...
MISC (111):
  • 坂本夏那, 大澤佳代, 重村克巳, 重村克巳, 北川孝一, 木下承晧, 亀岡正典, 楠木まり, 楠木まり, 宮良高維, et al. インドネシアにおけるヒト及び環境由来のESBL産生Escherichia coliの分布調査. 日本化学療法学会雑誌. 2021. 69. Supplement-A
  • Koichi Kitagawa, Mako Kato, Shota Komai, Ryota Sako, Hazuki Doi, Yoshiko Hashii, Takane Katayama, Toshiro Shirakawa. Preclinical Study of Oral Cancer Vaccine Using Recombinant Bifidobacterium Expressing WT1 Protein in Murine Bladder Cancer Model and Non-Human Primate. MOLECULAR THERAPY. 2020. 28. 4. 35-36
  • Toshiro Shirakawa, Masato Fujisawa. Genetic diagnosis of urinary tract infection. 2020. 33. 2. 117-120
  • Hikaru Minagawa, Yoshiko Hashii, Natsuki Nakagawa, Hiroko Nakajima, Yoshihiro Oka, Takane Katayama, Toshiro Shirakawa, Keiichi Ozono. The anti-tumor effect of oral cancer vaccine using Bifidobacterium as a platform for displaying Wilms' tumor 1 protein. JOURNAL OF CLINICAL ONCOLOGY. 2019. 37. 8
  • Koichi Kitagawa, Maho Tatsumi, Mako Kato, Shota Komai, Yoshiko Hashii, Takane Katayama, Toshiro Shirakawa. Cancer immunotherapy combining oral vaccination of recombinant Bifidobacterium longum displaying human Wilms' tumor 1 protein and anti-PD-1 checkpoint blockade for solid tumors in mice experimental model. CANCER IMMUNOLOGY RESEARCH. 2019. 7. 2
more...
Patents (5):
  • 免疫原性ポリペプチド表層発現ビフィズス菌(米国)
  • 免疫原性ポリペプチド表層発現ビフィズス菌
  • 腫瘍免疫誘導剤
  • ビフィズス菌表層提示融合タンパク質発現遺伝子
  • 経口ワクチン
Books (6):
  • Development of Cell Surface Engineering
    2020
  • 先端治療技術の実用化と開発戦略
    (株)技術情報協会 2017
  • 第7章 経口ワクチン
    株式会社 情報機構 2013
  • Cancer Gene Therapy / 14.Current therapeutic strategies in gene therapy for prostate cancer
    Research Signpost 2010
  • Welcome to ゲノムワールド / 5-3 遺伝子治療 5-4 再生医療
    廣川書店 2009
more...
Lectures and oral presentations  (170):
  • WT1 oral cancer vaccine combined with anti-PD-1 antibody completely suppressed tumor growth in a murine bladder cancer model
    (CIMT 2019 Annual Meeting 2019)
  • Cross-resistance and the mechanisms of cephalosporine-resistant urinary tract infection (UTI)-causative bacteria isolated in Indonesia
    (34th Annual EAU Congress 2019)
  • Comparison of molecular characteristics of carbapenem-resistant urinary tract infection- causing pathogens between Japan, Taiwan and Indonesia
    (34th Annual EAU Congress 2019)
  • 尿路感染症におけるカルバペネム耐性腸内細菌科細菌の分子生物学的検討ならびに迅速診断法の確立
    (第28回 泌尿器科分子・細胞研究会 2019)
  • 日本(神戸)とインドネシア(Yogyakarta)における尿路感染症の国際間比較
    (第34回日本環境感染学会総会・学術集会 2019)
more...
Education (2):
  • - 1999 神戸大学 大学院医学研究科博士課程外科学系修了
  • 1986 - 1992 Kobe University School of Medicine Faculty of Medicine
Professional career (1):
  • 博士(医学) (神戸大学)
Awards (4):
  • 2017/06 - 日本ビフィズス菌センター/腸内細菌学会 第21回腸内細菌学会 最優秀発表賞 Anti-tumor immune responses induced by oral cancer vaccine using recombinant Bifidobacterium displaying Wilms’ tumor 1 protein
  • 2008/06 - 日本遺伝子治療学会 第13回JSGT学会賞 学会発表演題
  • 2006/08 - (財)クリタ水・環境科学振興財団 クリタ水・環境科学振興財団 研究助成金 命にかかわる下痢性感染症予防のための水質汚染モニタリング法の開発
  • 2004 - 前立腺研究財団 前立腺研究財団優秀研究課題受賞 腫瘍特異的増殖型アデノウイルスおよびキャリアー細胞を用いた前立腺癌に対する遺伝子治療法の開発
Association Membership(s) (6):
アメリカ遺伝子治療学会 ,  日本癌治療学会 ,  日本癌学会 ,  日本感染症学会 ,  日本遺伝子治療学会 ,  日本泌尿器科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page